Nicotinic acid: Clinical considerations

Expert Opinion on Drug Safety

Volumn 11, Issue 4, 2012, Pages 551-564

  Kei, Anastazia ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Flushing; Glucose; Laropiprant; Niacin; Nicotinic acid; Uric acid

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR AFFECTING AGENT; ALLOPURINOL; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; LAROPIPRANT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NAPROXEN; NICOTINIC ACID; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACANTHOSIS NIGRICANS; BEDTIME DOSAGE; BLURRED VISION; CARDIOVASCULAR RISK; CHOLELITHIASIS; DIABETES MELLITUS; DIARRHEA; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DYSLIPIDEMIA; ESOPHAGITIS; EVENING DOSAGE; EXOPHTHALMOS; EYE DISEASE; EYEBROW DISEASE; EYELID DISEASE; FLUSHING; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERURICEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KERATITIS; MACULOPAPULAR RASH; MYOPATHY; NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PEPTIC ULCER; PROTHROMBIN TIME; RETINA MACULA CYSTOID EDEMA; REVIEW; SIDE EFFECT; SYNCOPE; TACHYPHYLAXIS; THROMBOCYTE; URTICARIA; VOMITING;

CARDIOVASCULAR DISEASES; GASTROINTESTINAL DISEASES; GLUCOSE; HOMEOSTASIS; HUMANS; HYPOTENSION; LIPIDS; LIVER; MUSCLE, SKELETAL; NIACIN; SKIN;

EID: 84862865263     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.682981     Document Type: Review

References (110)

1. Parhofer KG. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009;5:901-8
2. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol 1998;82:74U-81U
3. Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: The NAUTILUS study. Curr Med Res Opin 2006;22:417-25
4. Villines TC, Stanek EJ, Devine PJ, et al. the ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): Final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-6
5. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
6. Brown BG, Bardsley J, Poulin D, et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol
7. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
8. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
9. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010;210:353-61
10. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
11. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75
12. Tavintharan S, Sivakumar M, Lim SC, Sum CF. Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clin Chim Acta 2007;376:41-4
13. Owada A, Suda S, Hata T. Antiproteinuric effect of niceritrol, a nicotinic acid derivative, in chronic renal disease with hyperlipidemia: A randomized trial. Am J Med 2003;114:347-53
14. Cho KH, Kim HJ, Kamanna VS, Vaziri ND. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta 2010;1800:6-15
15. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110-22
16. Shehadah A, Chen J, Zacharek A, et al. Niaspan treatment induces neuroprotection after stroke. Neurobiol Dis 2010; [Epub ahead of print]
17. Salama RH, Nassar AY, Nafady AA, Mohamed HH. A novel therapeutic drug (copper nicotinic acid complex) for non-alcoholic fatty liver. Liver Int 2007;27:454-64
18. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
19. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003;303:364-9
20. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003;278:9869-74
21. Zechner R, Strauss JG, Haemmerle G, et al. Lipolysis: pathway under construction. Curr Opin Lipidol 2005;16:333-40
22. Carlson LA, Oro L. the effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962;172:641-5
23. Kamanna VS, Ganji SH, Kashyap ML. the mechanism and mitigation of niacin-induced flushing. Int J Clin Pract 2009;63:1369-77
24. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-45
25. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 1999;19:1051-9
26. Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:1672-8
27. Hernandez C, Molusky M, Li Y, et al. Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid. Cell Metab 2010;12:411-19
28. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006;58:342-74
29. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55
30. van der Hoorn JW, de Haan W, Berbee JF, et al. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE. 3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-22
31. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: Implications for raising HDL. J Lipid Res 2008;49:1195-201
32. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411-19
33. Lukasova M, Malaval C, Gille A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J Clin Invest 2011;121:1163-73
34. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8
35. Haas MJ, Alamir AR, Sultan S, et al. Nicotinic acid induces apolipoprotein A-I gene expression in HepG2 and Caco-2 cell lines. Metabolism 2011; [Epub ahead of print]
36. Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998;82:29U-34U; discussion 9U-41U
37. Stamler J. the coronary drug project-findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977;82:52-75
38. NIASPAN [package insert]. North Chicago, IL: Abbott Laboratories. Available from: http://www.rxabbott. com/pdf/niaspan.pdf [Last assessed 20 March 2012]
39. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
40. TREDAPTIVE [package insert]. Merck Sharp & Dohme Ltd. Available from: http://www.merck.com/newsroom/pdf/Tredaptive-pi.pdf [Last assessed 20 March 2012]
41. Berge KG, Canner PL. Coronary drug project: experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991;40(Suppl 1):S49-51
42. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. Available from: http://clinicaltrials.gov/ct2/show/NCT00461630 [Last assessed 20 March 2012]
43. Bays HE, Ballantyne C. What's the deal with niacin development: Is laropiprant add-on therapy a winning strategy to beat a straight flush? Curr Opin Lipidol 2009;20:467-76
44. Warady B, Kriley M, Alon U, Hellerstein S. Nicotinic acid-induced flush. Perit Dial Int 1989;9:81-2
45. Maciejewski-Lenoir D, Richman JG, Hakak Y, et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006;126:2637-46
46. Benyo Z, Gille A, Bennett CL, et al. Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells. Mol Pharmacol 2006;70:1844-9
47. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-40
48. Hanson J, Gille A, Zwykiel S, et al. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J Clin Invest 2010;120:2910-19
49. Cheng K, Wu TJ, Wu KK, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 2006;103:6682-7
50. Ishida H, Masuhiro Y, Fukushima A, et al. Identification and characterization of novel isoforms of human DP-1: DP-1 {alpha} regulates the transcriptional activity of E2F1 as well as cell cycle progression in a dominant-negative manner. J Biol Chem 2005;280:24642-8
51. Svedmyr N, Harthon L, Lundholm L. the relationship between the plasma concentration of free nicotinic acid and some of its pharmacologic effects in man. Clin Pharmacol Ther 1969;10:559-70
52. Pieper JA. Understanding niacin formulations. Am J Manag Care 2002;8:S308-14
53. Piepho RW. the pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am J Cardiol 2000;86:35L-40L
54. McKenney J. Niacin for dyslipidemia: Considerations in product selection. Am J Health Syst Pharm 2003;60:995-1005
55. Knopp RH, Ginsberg J, Albers JJ, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985;34:642-50
56. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:22C-31C
57. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7
58. Christensen NA, Achor RW, Berge KG, Mason HL. Nicotinic acid treatment of hypercholesteremia. Comparison of plain and sustained-action preparations and report of two cases of jaundice. JAMA 1961;177:546-50
59. Paolini JF, Bays HE, Ballantyne CM, et al. Extended-release niacin/laropiprant: Reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008;26:547-60
60. Paolini JF, Mitchel YB, Reyes R, et al. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: Results from a randomised placebo-controlled clinical trial. Int J Clin Pract 2008;62:896-904
61. Ballantyne CM, Davidson MH, McKenney J, et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol 2008;101:1428-36
62. US Food and Drud Administration. Niaspan. Available from: http://www.fda. gov/Safety/MedWatch/SafetyInformation/ucm203614.htm [Last assessed 20 March 2012]
63. US Food and Drud Administration. Niacor. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/anda/2000/040378-niacor-toc.cfm [Last assessed 20 March 2012]
64. Meyers CD, Carr MC, Park S, Brunzell JD. Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia. Ann Intern Med 2003;139:996-1002
65. American Heart Association. Drug therapy for cholesterol. Available from: http://www.heart.org/HEARTORG/Conditions/Cholesterol/ PreventionTreatmentofHighCholesterol/Drug-Therapy-for-Cholesterol-UCM-305632- Article.jsp#. T2o9-MUaPF9 [Last assessed 20 March 2012]
66. Stern RH, Spence JD, Freeman DJ, Parbtani A. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 1991;50:66-70
67. Cefali EA, Simmons PD, Stanek EJ, et al. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation. Int J Clin Pharmacol Ther 2007;45:78-88
68. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-6
69. Oberwittler H, Baccara-Dinet M. Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment. Int J Clin Pract 2006;60:707-15
70. Whelan AM, Price SO, Fowler SF, Hainer BL. the effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 1992;34:165-8
71. Thakkar RB, Kashyap ML, Lewin AJ, et al. Acetylsalicylic acid reduces niacin extended-release-induced flushing in patients with dyslipidemia. Am J Cardiovasc Drugs 2009;9:69-79
72. Eklund B, Kaijser L, Nowak J, Wennmalm A. Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 1979;17:821-30
73. Kaijser L, Eklund B, Olsson AG, Carlson LA. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979;57:114-17
74. Dunn RT, Ford MA, Rindone JP, Kwiecinski FA. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-80
75. Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;86:51L-6L
76. Taylor AJ, Stanek EJ. Flushing and the HDL-C response to extended-release niacin. J Clin Lipidol 2008;2:285-8
77. Van Hecken A, Depre M, De Lepeleire I, et al. the effect of MK-0524, a prostaglandin D(2) receptor antagonist, on prostaglandin D (2)-induced nasal airway obstruction in healthy volunteers. Eur J Clin Pharmacol 2007;63:135-41
78. Maccubbin D, Bays HE, Olsson AG, et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
79. Maccubbin D, Koren MJ, Davidson M, et al. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
80. Dishy V, Liu F, Ebel DL, et al. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009;49:416-22
81. FDA Rejects Merck's Cordaptive. Available from: http://www.businessweek. com/bwdaily/dnflash/content/apr2008/db20080429-182260.htm [Last assessed 21 March 2012]
82. Lai E, Wenning LA, Crumley TM, et al. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008;83:840-7
83. Stals H, Vercammen C, Peeters C, Morren MA. Acanthosis nigricans caused by nicotinic acid: Case report and review of the literature. Dermatology 1994;189:203-6
84. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98
85. Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc 2008;83:470-8
86. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-70
87. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
88. Canner PL, Furberg CD, Terrin ML, McGovern ME. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7
89. Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2006;97:477-9
90. Libby A, Meier J, Lopez J, et al. the effect of body mass index on fasting blood glucose and development of diabetes mellitus after initiation of extended-release niacin. Metab Syndr Relat Disord 2010;8:79-84
91. Guyton JR, Fazio S, Adewale AJ, et al. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care 2012; [Epub ahead of print]
92. Ambegaonkar BM, Wentworth C, Allen C, Sazonov V. Association between extended-release niacin treatment and glycemic control in patients with type 2 diabetes mellitus: Analysis of an administrative-claims database. Metabolism 2011;60:1038-44
93. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-61
94. Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. Am J Cardiol 1998;82:737-43
95. Gibbons LW, Gonzalez V, Gordon N, Grundy S. the prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995;99:378-85
96. Bays HE, Dujovne CA, McGovern ME, et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72
97. Rubenfire M. Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. Am J Cardiol 2004;94:306-11
98. Gentile S, Tiribelli C, Persico M, et al. Dose dependence of nicotinic acid-induced hyperbilirubinemia and its dissociation from hemolysis in Gilbert's syndrome. J Lab Clin Med 1986;107:166-71
99. Kei A, Elisaf M. Nicotinic acid/laropiprant decrease platelet count but increase mean platelet volume in patients with primary dyslipidemia. AMS 2011; [accepted for publication]
100. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988;62:28J-34J
101. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm 1995;52:1639-45
102. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up. JAMA 1990;264:3013-17
103. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5
104. Carlson LA. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114
105. Scott JT. Drug-induced gout. Baillieres Clin Rheumatol 1991;5:39-60
106. Bays HE, Maccubbin D, Meehan AG, et al. Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: A post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients. Clin Ther 2009;31:115-22
107. Kei A, Elisaf M, Moutzouri E, et al. Add-on-statin extended release nicotinic acid/laropiprant but not the switch to high-dose rosuvastatin lowers blood pressure: An Open-Label Randomized Study. Int J Hypertens 2011; [Epub ahead of print]
108. Kei A, Liberopoulos EN, Elisaf MS. What restricts the clinical use of nicotinic acid? Curr Vasc Pharmacol 2011; [Epub ahead of print]
109. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS. Do statins beneficially or adversely affect glucose homeostasis? Curr Vasc Pharmacol 2010;8:612-31
110. Tsouli SG, Liberopoulos EN, Mikhailidis DP, et al. Elevated serum uric acid levels in metabolic syndrome: An active component or an innocent bystander? Metabolism 2006;55:1293-301